This collaboration provides clinical validation for IDEAYA's PRMT5 program and access to Roche's pan-RAS inhibitor, but with no near-term financial catalysts. Monitor for Phase 1 data readouts and potential expansion into triplet combinations. The stock may see modest positive sentiment from the partnership, but fundamental value remains tied to clinical execution.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $28.40entry
- T+1 · 6mo ago +2.89%α +2.49% · $29.22
- T+5 · 5mo ago −2.82%α +1.00% · $27.60
- T+20 · 5mo ago +32.57%α +33.57% · $37.65
- T+60 · 3mo ago +47.08%α +44.58% · $41.77
Price Chart
How similar events traded
Executive Summary
IDEAYA announced a clinical collaboration with Roche to evaluate its PRMT5 inhibitor IDE892 in combination with Roche's pan-RAS inhibitor RG6505 for MTAP-deleted, RAS-mutant pancreatic cancer (PDAC). IDEAYA will sponsor the trial and Roche will supply RG6505; each party retains full commercial rights to its own compounds. This is an early-stage, non-financial collaboration that validates IDEAYA's MTAP-deletion portfolio but carries no near-term revenue or milestone payments.
Key Facts
- IDEAYA entered a clinical collaboration with Roche to evaluate IDE892 (PRMT5 inhibitor) + RG6505 (pan-RAS inhibitor) in MTAP-deleted RAS-mutant PDAC.
- IDEAYA sponsors the trial; Roche supplies RG6505.
- Each party retains all commercial rights to its own compounds; no financial terms disclosed.
- MTAP deletion estimated in up to 40% of PDAC; almost all MTAP-deleted PDAC harbor RAS mutations.
- IDE892 is in Phase 1 dose escalation; combination cohorts planned in PDAC, NSCLC, and other solid tumors.
- Triplet combination with IDE397 (MAT2A inhibitor) possible upon joint approval.
Financial Impact
No financial terms disclosed; no upfront, milestone, or royalty payments mentioned.
Risk Factors
- Early-stage clinical risk, preclinical results may not translate to human efficacy.
- No financial terms disclosed; collaboration provides no near-term revenue or milestone payments.
- Dependence on Roche for drug supply and joint governance may slow trial execution.
- Competitive landscape for PRMT5 and RAS-targeted therapies is evolving.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index-headers.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476-index.html | 0001193125-26-254476 |
| Document: 0001193125-26-254476.txt | 0001193125-26-254476 |
Track record
13 reports on IDYA
2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.66% at T+60 after the Apr 13, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $31.33 to $31.75 Now $30.36 −3.10% ▲ +1.34% +1.93% vs SPY
- Oct 6, 20265w ago 144 Bearish 6/10 Entry $36.26 to $33.86 Now $30.36 +16.27% ▲ +6.62% +5.64% vs SPY
- Aug 4, 202614w ago 8-K Neutral 4/10 Entry $36.11 to $36.84 Now $30.36 −15.92% ▲ +2.02% +2.12% vs SPY
- Jun 23, 202620w ago 8-K Neutral 2/10 Entry $36.28 to $36.17 Now $30.36 −16.32% ▼ −0.30% −2.01% vs SPY
- Jun 10, 202622w ago 8-K Bearish 6/10 Entry $28.84 to $31.26 Now $30.36 −5.27% ▼ −8.39% −7.96% vs SPY
- Jun 9, 202622w ago 424B5 Bearish 6/10 Entry $27.60 to $30.57 Now $30.36 −10.00% ▼ −10.76% −7.33% vs SPY
- Jun 8, 202623w ago 424B5 Bearish 6/10 Entry $28.07 to $30.23 Now $30.36 −8.16% ▼ −7.70% −5.28% vs SPY
- Jun 3, 202623w ago 8-K Neutral 4/10 Viewing Entry $28.40 to $27.60 Now $30.36 +6.90% ▼ −2.82% +1.00% vs SPY
- May 5, 202627w ago 8-K Neutral 2/10 Entry $28.74 to $28.12 Now $30.36 +5.64% ▼ −2.16% −3.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers